Document Detail


Pleiotropic effects of statins.
MedLine Citation:
PMID:  11122746     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The advent of statin therapy has revolutionized the ability of the clinician to manage patients at risk for the development of an ischemic event due to dyslipidemia. Large-scale clinical trials involving thousands of patients in both primary and secondary prevention have clearly demonstrated that statin therapy will reduce cardiovascular mortality across a broad spectrum of patient subgroups. Additionally, in adequately powered trials, total mortality has been successfully decreased by the use of statin therapy. However, the precise mechanism underlying the benefit of statin therapy has been controversial due to the multiplicity of potential benefits that statins have demonstrated in addition to pure lipid lowering. The causal theory of pharmacologic benefit reiterates the lipid hypothesis, which states that dyslipidemia is central to the process of atherosclerosis and the clinical benefit which accrues from statin therapy is a function of the degree of lipid lowering. The noncausal theory supports the premise that clinical benefits are related primarily to pleiotropic effects of statins (endothelial function, inflammation, coagulation and plaque vulnerability) as being the major modulators of clinical benefit. This review will focus on the potential beneficial effects of statin therapy on a number of the pleiotropic effects of statins and the potential role that these activities play in the reduction of risk for ischemic events.
Authors:
J A Farmer
Related Documents :
21135346 - Hour-specific bilirubin nomogram in infants with abo incompatibility and direct coombs-...
16561946 - Studies on the stability of the normal human fecal flora.
21547086 - Maternal preeclampsia and neonatal outcomes.
7802076 - Amnioinfusion and the intrauterine prevention of meconium aspiration.
16488406 - Development of a view-invariant representation of the human head.
3786036 - Individualized behavioral and environmental care for the very low birth weight preterm ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  2     ISSN:  1523-3804     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2000 May 
Date Detail:
Created Date:  2001-01-26     Completed Date:  2001-08-23     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  208-17     Citation Subset:  IM    
Affiliation:
Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Jfarmer@bcm.tmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Physiological Phenomena / drug effects*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*,  therapeutic use*
Myocardial Ischemia / drug therapy*,  physiopathology,  prevention & control
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype.
Next Document:  Chlamydia pneumoniae and atherosclerosis.